E. Hammond

Cancer Research · 2002–2009

A researcher in the Science corpus: 2 papers; trusts 0 researchers and is trusted by 0 researchers here, as inferred from the citation graph.

Papers from E. Hammond's perspective

Ordered by how strongly the researchers E. Hammond trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. (Cancer Research)
  2. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. (Annals of Oncology)
  3. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. (Journal of Clinical Oncology)
  4. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. (New England Journal of Medicine)
  5. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. (Journal of Clinical Oncology)
  6. The Statistical Analysis of Failure Time Data (Technometrics)
  7. Nonparametric Estimation from Incomplete Observations
  8. On the Criterion that a Given System of Deviations from the Probable in the Case of a Correlated System of Variables is Such that it Can be Reasonably Supposed to have Arisen from Random Sampling
  9. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data (The Lancet)
  10. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. (Cancer Research)

Their papers